This is a preview of subscription content, log in via an institution to check access.
Notes
European Academy of Allergy and Clinical Immunology
Reference
Agache I, et al. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI Biologicals Guidelines. Allergy : 12 Jul 2020. Available from: URL: http://doi.org/10.1111/all.14510
Rights and permissions
About this article
Cite this article
Dupilumab may be cost effective for atopic dermatitis. PharmacoEcon Outcomes News 859, 15 (2020). https://doi.org/10.1007/s40274-020-7024-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7024-x